The Alpha-Gal Syndrome and Hypersensitivity to Biomaterials: Understanding Xenoimmunity

Area of Science:

• Cardiovascular Medicine
• Immunology
• Biomaterials Science

Background:

• Nonhuman mammalian biomaterials are common in cardiovascular interventions but can trigger xenoimmune responses.
• Alpha-gal syndrome, an allergy to galactose-alpha-1,3-galactose, poses risks with porcine products and bioprosthetic valves.
• Other cardiovascular devices and medications can also elicit hypersensitivity reactions, leading to severe outcomes.

Purpose of the Study:

• To review the challenges posed by xenoimmune responses in cardiovascular interventions.
• To highlight the clinical implications of alpha-gal syndrome and other hypersensitivity reactions.
• To discuss strategies for recognition, prevention, and future advancements in managing immune-mediated complications.

Main Methods:

• Literature review of xenoimmunity in cardiovascular interventions.
• Analysis of immune responses to biomaterials, including alpha-gal syndrome.
• Discussion of clinical manifestations, diagnostic approaches, and preventive strategies.

Main Results:

• Xenoimmune responses, particularly alpha-gal syndrome, complicate cardiovascular procedures and can accelerate disease progression.
• Hypersensitivity reactions to various cardiovascular devices and medications are associated with significant morbidity and mortality.
• Current strategies include screening, multidisciplinary collaboration, and personalized prophylaxis.

Conclusions:

• Awareness and proactive management are crucial for preventing immune-mediated cardiovascular complications.
• Future research should focus on developing xenoantigen-free devices and predictive biomarkers.
• Coordinated clinical strategies involving cardiology and allergy specialists are essential for patient care.